1
Minerval:Minerval:
a novel clinical-stage, lipid regulator with game-a novel clinical-stage, lipid regulator with game-
...
2
Lipopharma [2007] is an pioneering clinical-stage biopharmaceutical
company based in Palma de Mallorca (Spain) that focu...
3
1. Based on an disruptive Technology platform: Membrane Lipid TherapyMembrane Lipid Therapy ((MLTMLT))
2. Game-changing ...
4
Effect of SMS1 genetic alterations on glioma patients’ survival
(Differential SGMS1 Gene Expression & Copy Number Analys...
5
Minerval vs. other targeted therapies in glioma
Mercer et al. BioDrugs 2010
Minerval
SMS
6
Minerval vs. other targeted therapies in glioma
Mercer et al. BioDrugs 2010
Minerval
SMS
7
Minerval, a new class of orally bioavailable lipid regulator multi-targetlipid regulator multi-target anticancer drug
fo...
8
Minerval on membrane lipids in human glioma cells (U118)
Time-dependent changes in sphingomyelin
(SM) content in U118 Ce...
9
Minerval regulates Ras localization in GLIOMA (SF767) cells
Translocation of K-Ras (green) from the membrane to the cyto...
10
Effect of Minerval in animal models of human brain tumours
(GLIOMA) compared with temozolomide and control group
Anti-c...
11
12
PI/II Clinical Study with Minerval
MIN-001-1203: “A phase I/IIa open-label dose escalation study of Minerval
in subject...
13
BiomarkersBiomarkers in MIN-001-1203 PI/II study in cancer
1) membrane lipids: SMSM → MOA/response [All cancers] >>> in...
14
Marked and significant reduction in several miRNA have been observed after analysis of plasma samples
from nude mice in...
15
MIN-001-1203. Minerval in cancer patients. Update:MIN-001-1203. Minerval in cancer patients. Update:
►3 cohorts complet...
16
Lipopharma & Minerval today:
• PI/II trials in glioma & solid tumors (MIN-001-1203) on-going since May 2013
• Orphan Dr...
17
Lipopharma
 Ctra. Valldemossa, Km. 7,4. ParcBIT. Edif. Disset. 2º C-8. E07121 – Palma de Mallorca. Spain
 +34 971 439...
Upcoming SlideShare
Loading in …5
×

Vicenç Tur / Minerval: a novel clinical-stage, lipid regulator with game-changing potential in glioma

1,115 views

Published on

Presentation given by Vicenç Tur from Lipopharma Therapeutics in the framework of the Emergence Forum Barcelona

Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014

Published in: Healthcare, Technology, Business
1 Comment
0 Likes
Statistics
Notes
  • sms gateways are cheap and nice with bulk sms in your pocket>>>> i realy like this site and i hope you do too.... www.smspanel.co.za
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

No Downloads
Views
Total views
1,115
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
8
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Vicenç Tur / Minerval: a novel clinical-stage, lipid regulator with game-changing potential in glioma

  1. 1. 1 Minerval:Minerval: a novel clinical-stage, lipid regulator with game-a novel clinical-stage, lipid regulator with game- changing potential inchanging potential in gliomaglioma Vicenç Tur.Vicenç Tur. CEO, Co-FounderCEO, Co-Founder Barcelona, 11Barcelona, 11thth April 2014April 2014
  2. 2. 2 Lipopharma [2007] is an pioneering clinical-stage biopharmaceutical company based in Palma de Mallorca (Spain) that focuses on the discovery, rational design and development of next generation medicinesnext generation medicines associated with a novel breakthrough therapeutic approach: the Membrane Lipid TherapyMembrane Lipid Therapy (MLT)
  3. 3. 3 1. Based on an disruptive Technology platform: Membrane Lipid TherapyMembrane Lipid Therapy ((MLTMLT)) 2. Game-changing novel MOAnovel MOA: SMS activation → regulation of membrane lipids → Multi-pathway modulation 3. Highly specific to cancer cells; very high efficacy in glioma (in cells & animals). Non Toxic. Crosses the BBB. 4. ORAL formulation. Simple Chemistry. Stable at ambient for +24 months 5. Clinical stage compound: MIN-001-1203 PI/IIa study on-going since May 2013 6. 5M€ sought for PIIb study in glioma (2014-2015) Minerval for the treatment of glioma
  4. 4. 4 Effect of SMS1 genetic alterations on glioma patients’ survival (Differential SGMS1 Gene Expression & Copy Number Analysis for SGMS1) National Cancer Institute. 2005. REMBRANDT <http://rembrandt.nci.nih.gov>. Accessed October 2012 SGSM1 up-regulated (n = 1) SGMS1 Intermediate (n = 258) All Glioma average (n=454) SGSM1 down-regulated (n = 84) Left panel: down-regulation of SGMS1 (green line) is associated with a marked and significant (P = 2 x 10-10) reduction in the life-span of glioma patients. SGSM1 Amplified (n = 73) All Glioma average (n=454) SGSM1 Deleted (n = 278) Right panel: deletion of the SGMS1 gene (green line) occurs in about 61% of all glioma patients and is associated with a significant reduction in their life-span, whereas patients with more than 2 copies of the SGMS1 gene (red line) have an increased life span and ca. 25% probability to live over 20 years.
  5. 5. 5 Minerval vs. other targeted therapies in glioma Mercer et al. BioDrugs 2010 Minerval SMS
  6. 6. 6 Minerval vs. other targeted therapies in glioma Mercer et al. BioDrugs 2010 Minerval SMS
  7. 7. 7 Minerval, a new class of orally bioavailable lipid regulator multi-targetlipid regulator multi-target anticancer drug for tumors with sphingomyelin metabolism alterationssphingomyelin metabolism alterations Specific activator of sphingomyelin synthase (SMS)sphingomyelin synthase (SMS) [1] SelectiveSelective regulation of lipid compositionlipid composition in cancer cell membranes:membranes: ▲▲SMSM; ▲▲DAGDAG; ▼▼PEPE; ▼PCPC [2] K-RasK-Ras localization ↓↓ MAPK – PI3K/AktMAPK – PI3K/Akt pathway normalization [3] CellCell cyclecycle arrestarrest [▼▼DHFRDHFR] & differentiationdifferentiation [4] PKC/Cyclin CDKPKC/Cyclin CDK Regulation [4] selective AutophagyAutophagy [5]
  8. 8. 8 Minerval on membrane lipids in human glioma cells (U118) Time-dependent changes in sphingomyelin (SM) content in U118 Cells after treatment with Minerval Increase induced on diacylglycerol (DAG) levels after Minerval treatments for 72 hours Levels of SM, phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylinositol (PI) and phosphatidylethanolamine (PE) after 72-h treatments with Minerval (2OHOA)
  9. 9. 9 Minerval regulates Ras localization in GLIOMA (SF767) cells Translocation of K-Ras (green) from the membrane to the cytosol and inner membranes after incubations of 10 minutes (1) or 24 hours (2). Ph. C.: phase contrast micrography. Increase in green fluorescence (K-Ras) after 10-minute incubations in the presence of Minerval does not correspond to increases in the expression of this protein. Proteins in the MAPK signalling pathway present a reduction in their activity, as measured by its phosphorilation status, while the expression of this proteins is not altered.
  10. 10. 10 Effect of Minerval in animal models of human brain tumours (GLIOMA) compared with temozolomide and control group Anti-cancer effect of Minerval in animal models of cancer
  11. 11. 11
  12. 12. 12 PI/II Clinical Study with Minerval MIN-001-1203: “A phase I/IIa open-label dose escalation study of Minerval in subjects with advanced solid tumors including malignant glioma” Top leading European KOL and investigational sites involved: Johann de Bono (Royal Marsden Hospital, London), Roger Stupp (University Hospital, Zurich), Jordi Rodon (Vall d'Hebron Institute of Oncology, Barcelona), Ruth Plummer (NCCC, Freeman Hospital, Newcastle) Part A. Dose escalating study. Up to 30 patients. 21-day treatments. Glioma and other solid tumors (lung, pancreas…) Part B. Exploratory study. Up to 20 patients in two groups. 21-day treatments. 1st group with glioma patients. 2nd group with biopsiable solid- tumors patients for biomarker evaluation.
  13. 13. 13 BiomarkersBiomarkers in MIN-001-1203 PI/II study in cancer 1) membrane lipids: SMSM → MOA/response [All cancers] >>> in tumor samples 2) GFAPGFAP → cancer cell differentiation [glioma] >>> in plasma samples 3) DHFRDHFR → cell proliferation [All cancers] >>> in tumor samples 4) miRNAmiRNA → diagnostic, response, pt segmentation [glioma, solid tumours] >>> in plasma samples
  14. 14. 14 Marked and significant reduction in several miRNA have been observed after analysis of plasma samples from nude mice inoculated with human lung cancer (A549) and glioma (SF767) cells. Treatment with Minerval (4 weeks) induced a significant recovery of miRNA levels. MiRNA identification not shown for confidentiality reasons (a patent filing is being considered) [ * → p=0,05 | ** → p=0,01 | *** → p=0,001 ] miRNA in Lung Cancer (A549) miRNAexpression (arbitraryunits) 1 2 3 4 5 6 0 2 4 6 8 10 12 control with tumor control without tumor treated 400 mg/Kg * * ** * ** **** ** ** ** *** * miRNA in glioma (SF767) miRNAexpression (arbitraryunits) 8 11 12 13 20 0 10 20 30 40 control with tumor control with tumor treated 400 mg/Kg ** * * ** ** ** **** ** ** miRNAexpression (arbitraryunits) 8 11 12 13 20 0 10 20 30 40 control with tumor control with tumor treated 400 mg/Kg ** * * ** ** ** **** ** **
  15. 15. 15 MIN-001-1203. Minerval in cancer patients. Update:MIN-001-1203. Minerval in cancer patients. Update: ►3 cohorts completed: 0.5, 1 & 2g/day (BID) ►10 pt have received at least 1 cycle of treatment with Minerval (3-week) (6 GBM, 2 mesothelioma, 1 pancreas, 1 SCLC ) ►no safety, tolerability, DLT or compliance issues ►pt #0102 (mesothelioma)pt #0102 (mesothelioma) on treatment since 02JUL13. Stable Disease (SD) so far. Dose escalated to 1g/day from cycle 7 (12NOV13) & to 2g/day from cycle 12 (24FEB14) ►pt #0202 (GBM)pt #0202 (GBM) on treatment since 03SEP13. Partial Response (PR) on RANO criteria. ►3 pt enroled in cohort #04 (4g/day, BID) On treatment since 11FEB14. No issues so far
  16. 16. 16 Lipopharma & Minerval today: • PI/II trials in glioma & solid tumors (MIN-001-1203) on-going since May 2013 • Orphan Drug status granted in EU (glioma) in Oct. 2011 • Subsidiary in the US (Lipopharma Inc.) established in 2011 • 10+ M Euro already raised in equity / grants (2007-2013) • World class strategic partners & collaborators' network • Looking for additional collaborations/investment (5M Euro in 2014) for PII studies in glioma & other solid tumors (2014-2015)
  17. 17. 17 Lipopharma  Ctra. Valldemossa, Km. 7,4. ParcBIT. Edif. Disset. 2º C-8. E07121 – Palma de Mallorca. Spain  +34 971 439 886 |34 971439974 |  info@lipopharma.com | www.lipopharma.com Thank you!

×